Indeed, altered ERAP1 expression influences the effectiveness of cytotoxic CD8+ T-cell anti-tumor immune responses in the context of solid cancer, melanoma and a T-cell lymphoma mouse model [40,46,47]. This evidence concerns the gene CD8A and T-cell non-Hodgkin lymphoma.